These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 14640921)

  • 1. Pharmacotherapy of chemotherapy-induced anaemia.
    Vansteenkiste J
    Expert Opin Pharmacother; 2003 Dec; 4(12):2221-7. PubMed ID: 14640921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.
    Wilson J; Yao GL; Raftery J; Bohlius J; Brunskill S; Sandercock J; Bayliss S; Moss P; Stanworth S; Hyde C
    Health Technol Assess; 2007 Apr; 11(13):1-202, iii-iv. PubMed ID: 17408534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guidelines and recommendations for the management of anaemia in patients with lymphoid malignancies.
    Henry DH
    Drugs; 2007; 67(2):175-94. PubMed ID: 17284083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS; Rocconi RP; Kilgore LC; Barnes MN
    Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Darbepoetin alfa: a new approach to the treatment of chemotherapy-induced anaemia.
    Vansteenkiste J; Rossi G; Foote M
    Expert Opin Biol Ther; 2003 Jun; 3(3):501-8. PubMed ID: 12783618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature.
    Ross SD; Allen IE; Henry DH; Seaman C; Sercus B; Goodnough LT
    Clin Ther; 2006 Jun; 28(6):801-31. PubMed ID: 16860166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
    Reed SD; Radeva JI; Daniel DB; Mody SH; Forlenza JB; McKenzie RS; Schulman KA
    Pharmacoeconomics; 2006; 24(5):479-94. PubMed ID: 16706573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice.
    Patton J; Reeves T; Wallace J
    Oncologist; 2004; 9(4):451-8. PubMed ID: 15266098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Darbepoetin alfa, a new therapy for the management of anemia of chronic kidney disease.
    Hudson JQ; Sameri RM
    Pharmacotherapy; 2002 Sep; 22(9 Pt 2):141S-149S. PubMed ID: 12222584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of darbepoetin alfa for the treatment of chemotherapy-induced anaemia.
    Vansteenkiste J; Wauters I
    Expert Opin Pharmacother; 2005 Mar; 6(3):429-40. PubMed ID: 15794734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
    Herrington JD; Davidson SL; Tomita DK; Green L; Smith RE; Boccia RV
    Am J Health Syst Pharm; 2005 Jan; 62(1):54-62. PubMed ID: 15658073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New oversight put in place for physicians giving anemia drugs to patients with cancer.
    Mitka M
    JAMA; 2010 Apr; 303(14):1355-6. PubMed ID: 20388885
    [No Abstract]   [Full Text] [Related]  

  • 13. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.
    Bokemeyer C; Aapro MS; Courdi A; Foubert J; Link H; Osterborg A; Repetto L; Soubeyran P;
    Eur J Cancer; 2007 Jan; 43(2):258-70. PubMed ID: 17182241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Darbepoetin alpha coming of age.
    Pedrazzoli P; Cinieri S; Lorusso V; Gamucci T; Secondino S; Silvestris N
    Anticancer Res; 2007; 27(6C):4419-24. PubMed ID: 18214054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel approaches to anemia associated with cancer and chemotherapy.
    Kolesar JM
    Am J Health Syst Pharm; 2002 Aug; 59(15 Suppl 4):S8-11. PubMed ID: 12166035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of cancer-related anemia: focus on the potential role of darbepoetin alfa.
    Valley AW
    Pharmacotherapy; 2002 Sep; 22(9 Pt 2):150S-159S. PubMed ID: 12222585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clinical studies.
    Scott SD
    Pharmacotherapy; 2002 Sep; 22(9 Pt 2):160S-165S. PubMed ID: 12222586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and economic impact of epoetins in cancer care.
    Marchetti M; Barosi G
    Pharmacoeconomics; 2004; 22(16):1029-45. PubMed ID: 15524492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.
    Wauters I; Vansteenkiste J
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1383-90. PubMed ID: 23113603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epoetins and [symbol: see text] darbepoetin alfa in malignant disease.
    Drug Ther Bull; 2004 Mar; 42(3):21-3. PubMed ID: 15038080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.